Disease · MONDO_0006325
Targets41
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 41
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CSF1R | Macrophage colony-stimulating factor 1 receptor | 1 | Macrophage colony stimulating factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/1436 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 1 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 1 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| ERBB4 | Receptor tyrosine-protein kinase erbB-4 | 1 | Receptor protein-tyrosine kinase erbB-4 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2066 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha modulator | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006325/targets